6.24
6.24 (0%)
As of Feb 14, 2025
Y-Mabs Therapeutics, Inc. [YMAB]
Source:
Company Overview
Y-mabs Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer.
| Country | United States |
| Headquarters | new york, new york |
| Phone Number | (646)-885-8505 |
| Industry | manufacturing |
| CEO | Michael Rossi |
| Website | www.ymabs.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $87.7 |
| Operating Profit | $-31.2 |
| Net Income | $-29.7 |
| Net Cash | $-11.4 |
Profit Ratios
| Gross Margin | $72.7 |
| Operating Margin | -35.6 |
| Profit as % of Revenues | -245% |
| Profit as % of Assets | -24% |
| Profit as % of Stockholder Equity | -32.2% |
Management Effectiveness
| Return on Equity | -32.2% |
| Return on Assets | -24.7% |
| Turnover Ratio | 70.8% |
| EBITA | $-31.2 |
Balance Sheet and Cash Flow Measures
| Total Assets | $119.9 |
| Total Liabilities | $27.9 |
| Operating Cash Flow | $-15.7 |
| Investing Cash Flow | |
| Financing Cash Flow | $4.3 |
